The global cell free expression market is expected to reach USD 275 million by 2023 anticipated to grow at a CAGR of 7.5% during the forecast period 2023-2035

In recent years, the biopharmaceutical sector has seen significant growth within the pharmaceutical industry. Notably, a substantial portion of newly approved drugs by the FDA’s Center for Drug Evaluation and Research are biologics, emphasizing their increasing importance. This has led to a rise in biologics and biosimilars development, heavily relying on living biological systems. Consequently, there’s been a heightened demand for various cell lines, with approximately 84% of therapeutic proteins produced in the last five years using diverse mammalian and microbial cells. However, a recent study discovered a concerning issue: around 30,000 research articles across various journals featured data derived from experiments using misidentified or contaminated cell lines. This poses a significant challenge in medical research, particularly as the field increasingly depends on cell-based assays and experiments. Hence, ensuring accurate characterization of cell lines has become imperative to maintain authenticity and precision in modern medical studies.
In the cost-intensive realm of pharmacological research and development, professionals are consistently seeking ways to improve operational efficiencies and reduce costs. Consequently, outsourcing has become a favored business model. Many service providers now claim expertise in developing and characterizing cell lines, tailored to the specific needs of drug developers. The technical landscape in this field is experiencing considerable innovation, particularly in automating various stages of cell line development. Additionally, advanced genome editing technologies like CRISPR/Cas-9 are extensively utilized to enhance the quality of recombinant cell lines. Unlike drug developers, service providers typically specialize in particular service portfolios. They prioritize staying abreast of the latest equipment and infrastructure advancements to ensure service quality. Furthermore, many service providers have recently forged strategic partnerships or undergone acquisitions with other entities to bolster their service offerings and expand their portfolios. Considering the prevalent trend of outsourcing and the ongoing efforts of service providers to enhance their services, it is anticipated that the contract services market for cell line development and characterization will steadily evolve until 2030.

Report Coverage

  • The study delves into the cell-free expression market, examining various aspects such as types of expression systems, host organisms, expression methods, end-users, and geographical regions. It analyzes factors like market drivers, restraints, opportunities, and challenges influencing market growth.
  • Furthermore, it evaluates the potential advantages and barriers within the market, providing insights into the competitive landscape for leading market players. The report forecasts revenue across major regions and offers an executive summary detailing key findings, market overview, challenges, advantages, healthcare and industry applications, and future prospects.
  • A detailed assessment includes parameters such as establishment year, company size, headquarters location, offered services (synthesis, template construction, scaled-up production), associated services (purification, quality control), host organisms, products synthesized, scale of operation, and industries served.
  • The evaluation considers cell-free system types, host organisms, expression methods, synthesized products, templates used, reaction formats, yields, reaction details, volume, temperature, reactions per kit, and pricing. It covers details about developers, establishment year, company size, and major players.
  • Additionally, service providers are evaluated based on supplier power and service strength, taking into account experience, host organisms, services offered, products synthesized, industries served, and scale of operation. Expression kits are analyzed concerning developer experience and competitiveness across various parameters.
  • The report provides detailed profiles of significant service providers and expression kit developers, focusing on their service/portfolio details, recent developments, and future outlook. It also covers partnerships since 2018, encompassing product development, research agreements, acquisitions, alliances, joint ventures, technology licensing, and commercialization agreements.
  • Furthermore, it examines funding types (seed, venture capital, IPOs, grants), amounts, stages, leading players, investors, and geographical distribution since 2018. An in-depth analysis of patents related to cell-free systems since 2015 includes publication years, types, jurisdictions, applicant types, focus areas, leading players, individual assignees, benchmarking, valuation, and citation analysis.


Key Market Companies

  • BioLinker
  • biotechrabbit
  • CellFreeSciences
  • Creative Biolabs
  • CUSABIO
  • Daicel Arbor Biosciences
  • LenioBio
  • Promega
  • Thermo Fisher Scientific
  • Touchlight